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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S267relationship between NFlB activity and mechanical allodynia was
observed with a Spearman r of -0.69 (p < 0.0001) (Fig. 1e). NF-lB
activity was moderately correlated to weight distribution with
a Spearman r of -0.39 (p ¼ 0.0002).
Conclusions: This study demonstrates the use of non-invasive lumi-
nescence in vivo imaging tomeasure NF-lB activity in amousemodel of
osteoarthritis and the comparison of a key molecular event in arthritis
to pain sensitivity development. MIA injection induced a transient
increase in NF-lB activity at early time points in the intra-articular joint
that was correlated with developing pain sensitivities in this model of
arthritis. The demonstrated relationship between NFlB activity,
mechanical allodynia, and weight bearing suggests the use of NFlB
luminescence imaging as a novel imaging biomarker of joint dysfunc-
tion in this model.
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Purpose: Non-steroidal anti-inﬂammatory drugs (NSAIDs) are
commonly prescribed for managing osteoarthritis (OA) pain; however,
their use is limited by potentially serious dose-related gastrointestinal,
cardiovascular, and renal adverse events (AEs). AUnited States Food and
Drug Administration Public Health Advisory recommended that NSAIDs
be administered at the lowest effective dose for the shortest duration.
Investigational submicron NSAIDs are being developed using proprie-
tary SoluMatrix technology that could provide effective pain relief at
lower doses than currently available oral prescription NSAIDs. Diclofe-
nac submicron particle capsules previously demonstrated analgesia in
a post-surgical model of mild to moderate pain. This Phase 3 study
evaluated diclofenac submicron particle capsules in patients with OA
pain.
Methods: This randomized, multi-center, double-blind, parallel-group
study enrolled 305 patients 41-90 years of age with OA of the hip or
knee. Patients had Kellgren-Lawrence grade II-III radiographic OA
severity, were chronic NSAID or acetaminophen users, with baseline
WOMAC pain subscores 50mm, that increased by 15mm following
NSAID discontinuation. Patients were randomized to diclofenac
submicron particle capsules 35mg TID or 35mg BID, or placebo. The
primary endpoint was mean change from baseline in WOMAC pain
score at week 12.Results: Most patients were women (203 [66.6%]) and Caucasian (245
[80.3%]) with a mean age of 61.6 (8.9) years. Diclofenac submicron
particle capsules 35mg TID demonstrated signiﬁcant pain improvement
(-44.1; P¼0.0024; Figure) compared with placebo (-32.5) at week 12.
There was numerical evidence of pain improvement for diclofenac
submicron particle capsules 35mg BID at week 12, although this did not
achieve statistical signiﬁcance (-39.0; 95% conﬁdence interval [CI], -33.3
to -44.8; P¼0.0795). Patients receiving diclofenac submicron particle
capsules 35mg TID (-37.4; 95%CI, -31.7 to -43.1; P<0.001) and diclofenac
submicron particle capsules 35mg BID (-31.4; 95%CI, -26.0 to -36.8;
P¼0.0052) experienced improvements in WOMAC pain subscale scores
at weeks 2, compared with placebo (-21.6; 95%CI, -27.1 to -16.1). At
week 6, patients administered diclofenac submicron particle capsules
35mg TID (-43.5; 95%CI, -37.5 to -49.5; P¼0.0011) maintained clinical
improvements in WOMAC pain subscale scores compared with placebo
(-31.1; 95%CI, -25.3 to -36.8). The average improvement in totalWOMAC
pain subscale scores favored diclofenac submicron particle capsules
35mg TID (-35.9; P¼0.0002) and 35mg BID (-30.3; P¼0.0363) compared
with placebo (-23.2). A higher proportion of patients who received
diclofenac submicron particle capsules 35mg TID (26.0%, 25/98) or BID
(22.5%, 23/104) reported their pain as “very much improved” compared
with placebo (6.3%, 6/103). The most frequent treatment-emergent AEs
were similar across treatment groups and included diarrhea, headache,
nausea, and upper respiratory tract infection.
ĂConclusions: Investigational lower-dose, diclofenac submicron particle
capsules provided better overall relief from OA pain compared with
placebo and were generally well-tolerated. These results suggest that
diclofenac submicron particle capsules are a potentially promising
therapeutic option for patients with OA pain.
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Purpose: Although often prescribed for treatment of acute pain, NSAIDs
have the potential for the development of dose-related gastrointestinal,
cardiovascular, and renal complications. A United States Food and Drug
Administration Public Health Advisory recommended that NSAIDs
should be administered at the lowest effective dose for the shortest
duration consistent with individual patient treatment goals. Investiga-
tional submicron NSAIDs are being developed using proprietary Sol-
uMatrix technology that could provide effective pain relief at lower
doses than currently available oral NSAIDs. In a Phase 2 study, indo-
methacin submicron particle capsules provided good pain relief and
were generally well-tolerated in a post-surgical model of mild to
moderate pain. This study evaluated the analgesic efﬁcacy and safety of
lower-dose, indomethacin submicron particle capsules and celecoxib
versus placebo in a validated post-surgical model of moderate to severe
pain.
Methods: This multi-center, double-blind study enrolled patients 18-68
years of age who underwent a primary, unilateral ﬁrst metatarsal
